1
|
Boustany Y, Laraqui A, El Rhaffouli H, Bajjou T, El Mchichi B, El Anaz H, Amine IL, Chahdi H, Oukabli M, Souhi H, Elouazzani H, Rhorfi IA, Abid A, Mahfoud T, Tanz R, Ichou M, Ennibi K, Belkadi B, Sekhsokh Y. Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa. Cancer Control 2022. [PMCID: PMC9520149 DOI: 10.1177/10732748221129464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Objectives This study aims to analyze the prevalence and spectrum of epidermal growth factor receptor (EGFR) mutations within the Middle East and North Africa region, compare the findings to other parts of the world, and explore the geographic disparities of EGFR mutations across the region. Methods We conducted a literature search using the terms “[EGFR] AND [mutation] AND [Non-Small Cell Lung Cancer] AND [Middle East OR North Africa]”, using PubMed, Science Direct, Web of science, Embase, Scopus, and Google scholar. Results A total of 15 eligible studies were included and 6122 patients with non-small cell lung cancer (NSCLC) were analyzed. Male patients were predominant in all of the considered studies, accounting for 70.4%. Of the included patients, 65.6% were smokers and 88.3% had been diagnosed with adenocarcinoma. Overall, EGFR mutations prevalence was 17.2%. In the Middle East, the reported frequency was 16.5%, ranging from 11.3% in Lebanon to 29.7% in the Gulf region. In North Africa, the prevalence of EGFR mutations was 18%, ranging from 17.5% in Egypt to 21.5% in Morocco. The most prevalent mutations were the exon 19 deletions (46.7%) followed by exon 21 substitutions (31.1%). Exon 20 alterations were detected in 10.8% of the analyzed cases, whereas exon 18 mutations were reported in 3.4% of the EGFR-mutated patients. There was 1.1% of patients that had concurrent EGFR mutations. Overall, EGFR mutation prevalence was higher in females [females vs males: 29.7% vs 5.9%, P<.001], non-smokers [non-smokers vs smokers: 31.3% vs 9.6%, P<.001], and patients with adenocarcinoma [adenocarcinoma vs non-adenocarcinoma: 18.8% vs 6.5%, P<.001]. Conclusion EGFR mutation prevalence among the Middle East and North Africa populations is slightly higher than that seen in NSCLC patients of Caucasian ethnicity but is lower than that identified in Asian NSCLC patients. The distribution of these mutations varies considerably throughout the region.
Collapse
Affiliation(s)
- Youssra Boustany
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
- Microbiology and Molecular Biology Team, Faculty of Sciences, Mohammed V University in Rabat, Morocco
| | - Abdelilah Laraqui
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Hicham El Rhaffouli
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Tahar Bajjou
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Bouchra El Mchichi
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Hicham El Anaz
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Idriss Lahlou Amine
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Hafsa Chahdi
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Mohammed Oukabli
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Hicham Souhi
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Hanane Elouazzani
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Ismail Abderrahmani Rhorfi
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Ahmed Abid
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Tarik Mahfoud
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Rachid Tanz
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Mohammed Ichou
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Khaled Ennibi
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Bouchra Belkadi
- Microbiology and Molecular Biology Team, Faculty of Sciences, Mohammed V University in Rabat, Morocco
| | - Yassine Sekhsokh
- Mohamed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| |
Collapse
|
2
|
Benbrahim Z, Antonia T, Mellas N. EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis. BMC Cancer 2018; 18:891. [PMID: 30217176 PMCID: PMC6137870 DOI: 10.1186/s12885-018-4774-y] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Accepted: 08/23/2018] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND Our goal was to investigate the prevalence of the epidermal growth factor receptor (EGFR) mutation in Middle East and African countries and to compare its prevalence with that shown in other populations. METHODS We used PubMed and the Cochrane Library databases to conduct a literature search using the terms "[EGFR] AND [mutation] AND [Non Small Cell Lung Cancer] AND [Middle East OR Africa]." We assessed studies published in English and French from 2004 until 2016. RESULTS Ten relevant studies were included in this systematic review. Overall, 1215 patients with non-small cell lung cancer (NSCLC) were included in this analysis. The overall ratio of male to female patients was 2.15. Of total patients included, 41.1% had never smoked and 85.8% had been diagnosed with adenocarcinoma. In 8 of the 10 studies, polymerase chain reaction (PCR) analyses were conducted to identify EGFR mutations. In total, 257 patients had an EGFR mutation, corresponding to a prevalence of 21.2%. The most frequent abnormality detected in all of the studies was in exon 19. In addition, all studies concluded the presence of a correlation between EGFR mutation status and female sex, non-smoking status, and adenocarcinoma subtype. CONCLUSIONS The EGFR mutation frequency in Middle East and African patients is higher than that shown in white populations but still lower than the frequency reported in Asian populations.
Collapse
Affiliation(s)
- Zineb Benbrahim
- Department of Medical Oncology, Hassan II University Hospital, Faculty of Medicine and Pharmacy of Fez, University Sidi Mohammed Ben Abdellah, Fez, Morocco.
| | - Teresita Antonia
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Nawfel Mellas
- Department of Medical Oncology, Hassan II University Hospital, Faculty of Medicine and Pharmacy of Fez, University Sidi Mohammed Ben Abdellah, Fez, Morocco
| |
Collapse
|